Moderna Therapeutics, a multibillion-dollar biotech startup, is raising $500 million in a round that values the company at $7.5 billion, according to the data provider Pitchbook.

The financing, first reported by Bloomberg, comes as Moderna burns through about $450 million a year in an effort to craft medicines that can transform the body’s cells into drug factories. The company has raised more than $1.5 billion since its inception in 2010, repeatedly putting off a public offering as it worked through setbacks that delayed its most ambitious science.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • You continue to be the Sean Hannity of biotech quasi journalism. Spin for the win dude. Maybe you’re right, this whole thing at Moderna is a multibillion dollar scam.. Unfortunately, they are not Theranos, this is not and never was investigative journalism and there is no Pulitzer on the horizon.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy